



**Larka**

**Press release**

Merger & Acquisition

31<sup>st</sup> of July, 2019

# Larka provided Keensight with an **Integrated due-** **diligence** for their investment in 3P Biopharmaceuticals.



**KEENSIGHT**

CAPITAL

Biopharmaceuticals



**3P**



## **Integrated due-diligence**

Value creating insights come from an integrated, 360-degree view, diligence process that aggregates strategic, commercial, technical and organizational analysis, and gauges how pulling a lever in one specific area of the business will affect all other operations and assumptions within the whole organization.

Larka has developed a unique Integrated Due-Diligence solution for Private Equity firms, built on nearly 30 years of in-depth strategic, commercial, technical and organizational diagnostics performed on hundreds of industry players – *BioPharma companies, CROs, CDMOs, CMOs, analytical testing Labs, and equipment suppliers.*

Our Integrated Due-Diligence solution combines Commercial Due-Diligence, Technical Due-Diligence and Operational Due-Diligence under one roof. It provides PE firms with both, a full appreciation of the capabilities, synergies and risks involved and a full-potential vision for the business, along with the capital, time, resources and organization it will take to run the optimal post-acquisition plan.

## **Contact**

Pierre-Anthony Brioir, Director  
+33 650 630 286  
[pabrioir@larka.fr](mailto:pabrioir@larka.fr)

Adrien Chalmont, Manager  
+33 621 006 115  
[achalmont@larka.fr](mailto:achalmont@larka.fr)

# **Larka is pleased to announce that it performed the Commercial Due-Diligence, Operational Due-Diligence and Technical Due-Diligence for Keensight Capital, the new majority shareholder of 3P Biopharmaceuticals.**

Larka advised Keensight Capital on all relevant strategic, commercial and operational aspects of the transaction. In addition, Larka also performed the Technical, Quality & Regulatory Due-Diligence.

Keensight Capital, one of the leading private equity managers dedicated to pan-European Growth Buyout investments, acquired Infarco's majority stake in 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization – *CDMO* – specialized in the process development and GMP manufacturing of biologics for both microbial and mammalian expression systems.

Founded in 2006 and based near Pamplona, Spain, 3P Biopharmaceuticals employs 240 people and offers a complete biologics production service, from preclinical and clinical stages, all the way to full-scale commercial manufacturing.

Larka performed an **Integrated due-diligence** to support Keensight Capital during the acquisition of 3P Biopharmaceuticals.

Javier Lopez Moras, Director at Keensight Capital, said: "We are proud to be the new shareholders of 3P Biopharmaceuticals, one of the European leaders in the biologics CDMO space. We have been happy to work with Larka on this investment opportunity. Pierre-Anthony Brioir and his team confirmed once again the level of excellence and expertise they have in this field."

Pierre-Anthony Brioir, Director at Larka, commented: "After our successful collaboration last year on another transaction in this field, we are very proud to have worked again with Keensight on this new successful deal. 3P Biopharmaceuticals has a strong growth potential, with a wide range of services covering the whole value chain, from preclinical work to commercial supply. Combined with the highly skilled and experienced team of Keensight, 3P Biopharmaceuticals should become a major CDMO player in Europe in the coming years."

## **About Larka**

Larka is a management consulting firm, exclusively dedicated to the Biotech and Pharma industry. We assist small Biotech or large Pharma companies, Contract Services Providers or Equipment Suppliers, Venture Capital or Private Equity firms, in their development or in managing complex situations. Active in Technical, Organizational, Commercial and Strategic operations, Larka has developed a unique combination of expertise which covers CMC & Outsourcing activities, Operational & Commercial excellence, Marketing & Sales, Corporate Strategy and M&A.

For more information, please visit [www.larka.com](http://www.larka.com)

## **About Keensight Capital**

Keensight Capital, one of the leading European Growth Buyout firms, is committed to supporting entrepreneurs as they implement their growth strategies. For 20 years, Keensight Capital's team of seasoned professionals has leveraged their knowledge of investment and growth industries to invest for the long term in profitable companies with high growth potential and revenues in the range of €15 million to €250 million. Drawing on its expertise in the Information Technology/Internet and Healthcare/Wellbeing sectors, Keensight identifies the best investment opportunities in Europe and works closely with management teams to develop and achieve their strategic vision.

For more information, please visit <https://keensightcapital.com>